1.Compston A. Genetic epidemiology of multiple sclerosis. Journal of neurology, neurosurgery, and psychiatry. 1997;62(6):553.
2.Sadovnick AD, Dyment D, Ebers G. Genetic epidemiology of multiple sclerosis. Epidemiologic reviews. 1997;19(1):99-106.
3.Mohammed EMJ. Multiple sclerosis is prominent in the Gulf states. Pathogenesis. 2016;3(2):19-38.
4.Saberi A, Akhondzadeh S, Kazemi S. Infectious agents and different course of multiple sclerosis: a systematic review. Acta neurologica Belgica. 2018; 118(3), 361-377.
5.Warabi Y, Yamazaki M, Shimizu T, Nagao M. Abnormal nerve conduction study findings indicating the existence of peripheral neuropathy in multiple sclerosis and neuromyelitis optica. BioMed research international. 2013;2013.
6.Koriem KMM. Multiple sclerosis: New insights and trends. Asian Pacific Journal of Tropical Biomedicine. 2016;6(5):429-40.
7. Ramagopalan SV, Dobson R, Meier UC, Giovannoni G. Multiple sclerosis: risk factors, prodromes, and potential causal pathways. The Lancet Neurology. 2010;9(7):727-39.
8.Ascherio A, Munger KL. Epstein–Barr virus infection and multiple sclerosis: a review. Journal of Neuroimmune Pharmacology. 2010;5(3):271-7.
9.Rubicz R, Yolken R, Drigalenko E, Carless MA, et, al. A genome-wide integrative genomic study localizes genetic factors influencing antibodies against Epstein-Barr virus nuclear antigen 1 (EBNA-1). PLoS genetics. 2013;9(1):e1003147.
10.Marrosu MG, Cocco E, Costa G, Murru MR, et, al. Interaction of loci within the HLA region influences multiple sclerosis course in the Sardinian population. Journal of neurology. 2006;253(2):208-13.
11.Ochs-Balcom HM, Wiesner G, Elston R. Human Genome Epidemiology (HuGE) Review. American Journal of Epidemiology. 2007;166(3):246-54.
12.Kalanie H, Kamgooyan M, Sadeghian H, Kalanie A. Histocompatibility antigen (HLA) associations with multiple sclerosis in Iran. Multiple Sclerosis Journal. 2000;6(5):317-9.
13.Baranzini S. Revealing the genetic basis of multiple sclerosis: are we there yet? Current opinion in genetics & development. 2011; 21(3):317-24.
14.Sadovnick AD, Ebers G. Epidemiology of multiple sclerosis: a critical overview. Canadian Journal of Neurological Sciences. 1993;20(1):17-29.
15.Russell B. The pathogenesis of multiple sclerosis revisited. JR Coll Physicians Edinb. 2002;32:244-65.
16.Varzi AM, Shahsavar F, Tarrahi M. Distribution of HLA-DRB1 and HLA-DQB1 alleles in Lak population of Iran. Human immunology. 2016;77(7):580-3.
17.Amirzargar A, Mytilineos J, Yousefipour A, Farjadian S, et, al. HLA class II (DRB1, DQA1 and DQB1) associated genetic susceptibility in Iranian multiple sclerosis (MS) patients. European journal of immunogenetics. 1998;25(4):297-301.
18.Werneck LC, Lorenzoni PJ, Arndt RC, Kay CSK, et, al. The immunogenetics of multiple sclerosis. The frequency of HLA-alleles class 1 and 2 is lower in Southern Brazil than in the European population. Arquivos de neuro-psiquiatria. 2016;74(8):607-16.
19.Kollaee A, Ghaffarpor M, Ghlichnia H, Ghaffari S, et, al. The influence of the HLA-DRB1 and HLA-DQB1 allele heterogeneity on disease risk and severity in Iranian patients with multiple sclerosis. International journal of immunogenetics. 2012;39(5):414-22.
